Myocyte deficiency as a target in the treatment of cardiomyopathy

Progress in Pediatric Cardiology

Volumn 23, Issue 1-2, 2007, Pages 49-59

  Rodrigues, Claudia O ^a   Shehadeh, Lina A ^a   Webster, Keith A ^a   Bishopric, Nanette H ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cardiomyopathy; Cell death; Drug therapy; Genetics; Stem cells

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; OMAPATRILAT;

APOPTOSIS; ARTICLE; CARDIOMYOPATHY; CELL LOSS; CELL POPULATION; CELL TRANSPLANTATION; GENE TARGETING; GENETIC DISORDER; HEART FAILURE; HEART MUSCLE; HEART MUSCLE CELL; HEART VENTRICLE TACHYCARDIA; HUMAN; MUSCLE CELL; MYOCARDIAL DISEASE; NONHUMAN; NONVIRAL GENE THERAPY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STEM CELL;

EID: 34547479770     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ppedcard.2007.05.001     Document Type: Article

References (175)

1. Burch M. Heart failure in the young. Heart 88 (2002) 198-202
2. Guntheroth W.G. Improved outcomes of pediatric dilated cardiomyopathy and heart transplantation. J Am Coll Cardiol 45 (2005) 1733-1734
3. Weng K.P., Lin C.C., Huang S.H., and Hsieh K.S. Idiopathic dilated cardiomyopathy in children: a single medical center's experience. J Chin Med Assoc 68 (2005) 368-372
4. Towbin J.A., Lowe A.M., Colan S.D., et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 296 (2006) 1867-1876
5. Boucek M.M., Faro A., Novick R.J., Bennett L.E., Keck B.M., and Hosenpud J.D. The Registry of the International Society for Heart and Lung Transplantation: Fourth Official Pediatric Report-2000. J Heart Lung Transplant 20 (2001) 39-52
6. Kannel W.B. Epidemiological aspects of heart failure. Cardiol Clin 7 (1989) 1-9
7. Mair F.S., Crowley T.S., and Bundred P.E. Prevalence, aetiology and management of heart failure in general practice. Br J Gen Pract 46 (1996) 77-79
8. Mattila S., Heikkila L., Sipponen J., et al. Heart transplantation in Finland 1985-1995. Ann Chir Gynaecol 86 (1997) 113-120
9. Aronow W.S. The older man's heart and heart disease. Med Clin North Am 83 (1999) 1291-1303
10. Splawski I., Shen J., Timothy K.W., et al. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 102 (2000) 1178-1185
11. Priori S.G., Schwartz P.J., Napolitano C., et al. Risk stratification in the long-QT syndrome. N Engl J Med 348 (2003) 1866-1874
12. Cox G.F., Sleeper L.A., Lowe A.M., et al. Factors associated with establishing a causal diagnosis for children with cardiomyopathy. Pediatrics 118 (2006) 1519-1531
13. Anversa P., Loud A.V., Levicky V., and Guideri G. Left ventricular failure induced by myocardial infarction. II. Tissue morphometry. Am J Physiol 248 (1985) H883-H889
14. Rose A.G., and Beck W. Dilated (congestive) cardiomyopathy: a syndrome of severe cardiac dysfunction with remarkably few morphological features of myocardial damage. Histopathology 9 (1985) 367-379
15. Rakusan K., Flanagan M.F., Geva T., Southern J., and Van Praagh R. Morphometry of human coronary capillaries during normal growth and the effect of age in left ventricular pressure-overload hypertrophy. Circulation 86 (1992) 38-46
16. Olivetti G., Melissari M., Balbi T., et al. Myocyte cellular hypertrophy is responsible for ventricular remodelling in the hypertrophied heart of middle aged individuals in the absence of cardiac failure. Cardiovasc Res 28 (1994) 1199-1208
17. Tiyyagura S.R., and Pinney S.P. Left ventricular remodeling after myocardial infarction: past, present, and future. Mt Sinai J Med 73 (2006) 840-851
18. Hilfiker-Kleiner D., Landmesser U., and Drexler H. Molecular mechanisms in heart failure focus on cardiac hypertrophy, inflammation, angiogenesis, and apoptosis. J Am Coll Cardiol 48 (2006) A56-A66
19. Venugopalan P., Agarwal A.K., and Worthing E.A. Chronic cardiac failure in children due to dilated cardiomyopathy: diagnostic approach, pathophysiology and management. Eur J Pediatr 159 (2000) 803-810
20. Rusconi P., Gomez-Marin O., Rossique-Gonzalez M., et al. Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. J Heart Lung Transplant 23 (2004) 832-838
21. Franz W.M., Muller O.J., and Katus H.A. Cardiomyopathies: from genetics to the prospect of treatment. Lancet 358 (2001) 1627-1637
22. Towbin J.A., and Bowles N.E. Molecular genetics of left ventricular dysfunction. Curr Mol Med 1 (2001) 81-90
23. Ahmad F., Seidman J.G., and Seidman C.E. The genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet 6 (2005) 185-216
24. Miller T.E., You L., Myerburg R.J., Benke P.J., and Bishopric N.H. Whole blood RNA offers a rapid, comprehensive approach to genetic diagnosis of cardiovascular diseases. Genet Med 9 (2007) 23-33
25. Protonotarios N., Tsatsopoulou A., Anastasakis A., et al. Genotype-phenotype assessment in autosomal recessive arrhythmogenic right ventricular cardiomyopathy (Naxos disease) caused by a deletion in plakoglobin. J Am Coll Cardiol 38 (2001) 1477-1484
26. Ackerman M.J. Genetic testing for risk stratification in hypertrophic cardiomyopathy and long QT syndrome: fact or fiction?. Curr Opin Cardiol 20 (2005) 175-181
27. Phillips K.A., Ackerman M.J., Sakowski J., and Berul C.I. Cost-effectiveness analysis of genetic testing for familial long QT syndrome in symptomatic index cases. Heart Rhythm 2 (2005) 1294-1300
28. Tardiff J.C. Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes. Heart Fail Rev 10 (2005) 237-248
29. Sanoudou D., Vafiadaki E., Arvanitis D.A., Kranias E., and Kontrogianni-Konstantopoulos A. Array lessons from the heart: focus on the genome and transcriptome of cardiomyopathies. Physiol Genomics 21 (2005) 131-143
30. James T.N. Normal and abnormal consequences of apoptosis in the human heart. From postnatal morphogenesis to paroxysmal arrhythmias. Circulation 90 (1994) 556-573
31. Olivetti G., Melissari M., Capasso J.M., and Anversa P. Cardiomyopathy of the aging human heart. Myocyte loss and reactive cellular hypertrophy. Circ Res 68 (1991) 1560-1568
32. Torella D., Rota M., Nurzynska D., et al. Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 overexpression. Circ Res 94 (2004) 514-524
33. Yao M., Keogh A., Spratt P., dos Remedios C.G., and Kiessling P.C. Elevated DNase I levels in human idiopathic dilated cardiomyopathy: an indicator of apoptosis?. J Mol Cell Cardiol 28 (1996) 95-101
34. Narula J., Pandey P., Arbustini E., et al. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy [see comments]. Proc Natl Acad Sci U S A 96 (1999) 8144-8149
35. Reed J.C., and Paternostro G. Postmitochondrial regulation of apoptosis during heart failure [comment]. Proc Natl Acad Sci U S A 96 (1999) 7614-7616
36. Hughes S.E. Detection of apoptosis using in situ markers for DNA strand breaks in the failing human heart. Fact or epiphenomenon?. J Pathol 201 (2003) 181-186
37. Koda M., Takemura G., Kanoh M., et al. Myocytes positive for in situ markers for DNA breaks in human hearts which are hypertrophic, but neither failed nor dilated: a manifestation of cardiac hypertrophy rather than failure. J Pathol 199 (2003) 229-236
38. Nishigaki K., Minatoguchi S., Seishima M., et al. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. J Am Coll Cardiol 29 (1997) 1214-1220
39. Olivetti G., Abbi R., Quaini F., et al. Apoptosis in the failing human heart. N Engl J Med 336 (1997) 1131-1141
40. Knowlton A.A., Kapadia S., Torre-Amione G., et al. Differential expression of heat shock proteins in normal and failing human hearts. J Mol Cell Cardiol 30 (1998) 811-818
41. Mori K., Komamura K., Ohta N., Yoneda K., Miyatake K., and Katayama Y. Relationship between apoptosis-related markers and cardiomyopathy. Rinsho Byori 46 (1998) 1235-1240
42. Toyozaki T., Hiroe M., Saito T., et al. Levels of soluble Fas in patients with myocarditis, heart failure of unknown origin, and in healthy volunteers. Am J Cardiol 81 (1998) 798-800
43. Milting H., Bartling B., Schumann H., et al. Altered levels of mRNA of apoptosis-mediating genes after mid-term mechanical ventricular support in dilative cardiomyopathy-first results of the Halle Assist Induced Recovery Study (HAIR). Thorac Cardiovasc Surg 47 (1999) 48-50
44. Latif N., Khan M.A., Birks E., et al. Upregulation of the Bcl-2 family of proteins in end stage heart failure. J Am Coll Cardiol 35 (2000) 1769-1777
45. Schumann H., Holtz J., Zerkowski H.R., and Hatzfeld M. Expression of secreted frizzled related proteins 3 and 4 in human ventricular myocardium correlates with apoptosis related gene expression. Cardiovasc Res 45 (2000) 720-728
46. Sliwa K., Skudicky D., Bergemann A., Candy G., Puren A., and Sareli P. Peripartum cardiomyopathy: analysis of clinical outcome, left function, plasma levels of cytokines and Fas/APO-1 vol. 35 (2000) 701-705
47. Akyurek O., Akyurek N., Sayin T., et al. Association between the severity of heart failure and the susceptibility of myocytes to apoptosis in patients with idiopathic dilated cardiomyopathy. Int J Cardiol 80 (2001) 29-36
48. Ho Y.L., Chen C.L., Hsu R.B., Lin L.C., and Huang P.J. The correlation between expression of apoptosis-related proteins and myocardial functional reserve evaluated by dobutamine stress echocardiography in patients with dilated cardiomyopathy. J Am Soc Echocardiogr 16 (2003) 931-936
49. Steenbergen C., Afshari C.A., Petranka J.G., et al. Alterations in apoptotic signaling in human idiopathic cardiomyopathic hearts in failure. Am J Physiol Heart Circ Physiol 284 (2003) H268-H276
50. Steenman M., Chen Y.W., Le Cunff M., et al. Transcriptomal analysis of failing and nonfailing human hearts. Physiol Genomics 12 (2003) 97-112
51. Tung T.C., Cui G., Oshima K., Laks H., and Sen L. Balanced expression of mitochondrial apoptosis regulatory proteins correlates with long-term survival of cardiac allografts. Am J Physiol Heart Circ Physiol 285 (2003) H2832-H2841
52. Kanoh M., Takemura G., Misao J., et al. Significance of myocytes with positive DNA in situ nick end-labeling (TUNEL) in hearts with dilated cardiomyopathy: not apoptosis but DNA repair. Circulation 99 (1999) 2757-2764
53. Kavantzas N.G., Lazaris A.C., Agapitos E.V., Nanas J., and Davaris P.S. Histological assessment of apoptotic cell death in cardiomyopathies. Pathology 32 (2000) 176-180
54. Francis G.S., Anwar F., Bank A.J., Kubo S.H., and Jessurun J. Apoptosis, Bcl-2, and proliferating cell nuclear antigen in the failing human heart: observations made after implantation of left ventricular assist device. J Card Fail 5 (1999) 308-315
55. Alter P., Jobmann M., Meyer E., Pankuweit S., and Maisch B. Apoptosis in myocarditis and dilated cardiomyopathy: does enterovirus genome persistence protect from apoptosis? An endomyocardial biopsy study. Cardiovasc Pathol 10 (2001) 229-234
56. Saraste A., Voipio-Pulkki L.M., Heikkila P., Laine P., Nieminen M.S., and Pulkki K. Soluble tumor necrosis factor receptor levels identify a subgroup of heart failure patients with increased cardiomyocyte apoptosis. Clin Chim Acta 320 (2002) 65-67
57. Di Napoli P., Taccardi A.A., Grilli A., et al. Left ventricular wall stress as a direct correlate of cardiomyocyte apoptosis in patients with severe dilated cardiomyopathy. Am Heart J 146 (2003) 1105-1111
58. Wu Z.K., Laurikka J., Saraste A., et al. Cardiomyocyte apoptosis and ischemic preconditioning in open heart operations. Ann Thorac Surg 76 (2003) 528-534
59. Kyto V., Saraste A., Saukko P., et al. Apoptotic cardiomyocyte death in fatal myocarditis. Am J Cardiol 94 (2004) 746-750
60. Okada H., Takemura G., Koda M., et al. Myocardial apoptotic index based on in situ DNA nick end-labeling of endomyocardial biopsies does not predict prognosis of dilated cardiomyopathy. Chest 128 (2005) 1060-1062
61. Hirota H., Chen J., Betz U.A., et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 97 (1999) 189-198
62. Wencker D., Chandra M., Armstrong R.C., et al. Rescue of dilated cardiomyopathy by caspase inhibition in FKBP-caspase 8 transgenic mice. Circulation 102 Suppl II (2000) II-8
63. Wencker D., Chandra M., Nguyen K., et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 111 (2003) 1497
64. Oh H., Wang S.C., Prahash A., et al. Telomere attrition and Chk2 activation in human heart failure. Proc Natl Acad Sci U S A 100 (2003) 5378-5383
65. Bishopric N.H., Andreka P., Slepak T., and Webster K.A. Molecular mechanisms of apoptosis in the cardiac myocyte. Curr Opin Pharmacol 1 (2001) 141-150
66. Edinger A.L., and Thompson C.B. Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol 16 (2004) 663-669
67. Modjtahedi N., Giordanetto F., Madeo F., and Kroemer G. Apoptosis-inducing factor: vital and lethal. Trends Cell Biol 16 (2006) 264-272
68. Webster K.A., Graham R.M., Thompson J.W., et al. Redox stress and the contributions of BH3-only proteins to infarction. Antioxid Redox Signal 8 (2006) 1667-1676
69. Wang Y., Li X., Wang L., et al. An alternative form of paraptosis-like cell death, triggered by TAJ/TROY and enhanced by PDCD5 overexpression. J Cell Sci 117 (2004) 1525-1532
70. Kostin S., Pool L., Elsasser A., et al. Myocytes die by multiple mechanisms in failing human hearts. Circ Res 92 (2003) 715-724
71. Cuervo A.M. Autophagy: many paths to the same end. Mol Cell Biochem 263 (2004) 55-72
72. Miyata S., Takemura G., Kawase Y., et al. Autophagic cardiomyocyte death in cardiomyopathic hamsters and its prevention by granulocyte colony-stimulating factor. Am J Pathol 168 (2006) 386-397
73. Yu L., Wan F., Dutta S., et al. Autophagic programmed cell death by selective catalase degradation. Proc Natl Acad Sci U S A 103 (2006) 4952-4957
74. Webster K.A., Discher D.J., Kaiser S., Hernandez O., Sato B., and Bishopric N.H. Hypoxia-activated apoptosis of cardiac myocytes requires reoxygenation or a pH shift and is independent of p53. J Clin Invest 104 (1999) 239-252
75. Hilfiker-Kleiner D., Hilfiker A., Fuchs M., et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res 95 (2004) 187-195
76. Yaoita H., Ogawa K., Maehara K., and Maruyama Y. Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation 97 (1998) 276-281
77. Holly T.A., Drincic A., Byun Y., et al. Caspase inhibition reduces myocyte cell death induced by myocardial ischemia and reperfusion in vivo. J Mol Cell Cardiol 31 (1999) 1709-1715
78. Huang J.Q., Radinovic S., Rezaiefar P., and Black S.C. In vivo myocardial infarct size reduction by a caspase inhibitor administered after the onset of ischemia. Eur J Pharmacol 402 (2000) 139-142
79. Okamura T., Miura T., Takemura G., et al. Effect of caspase inhibitors on myocardial infarct size and myocyte DNA fragmentation in the ischemia-reperfused rat heart. Cardiovasc Res 45 (2000) 642-650
80. Hayakawa Y., Chandra M., Miao W., et al. Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Galpha(q) transgenic mice. Circulation 108 (2003) 3036-3041
81. Mani K., and Kitsis R.N. Myocyte apoptosis: programming ventricular remodeling. J Am Coll Cardiol 41 (2003) 761-764
82. Chandrashekhar Y., Sen S., Anway R., Shuros A., and Anand I. Long-term caspase inhibition ameliorates apoptosis, reduces myocardial troponin-I cleavage, protects left ventricular function, and attenuates remodeling in rats with myocardial infarction. J Am Coll Cardiol 43 (2004) 295-301
83. Gottlieb R.A., Gruol D.L., Zhu J.Y., and Engler R.L. Preconditioning rabbit cardiomyocytes: role of pH, vacuolar proton ATPase, and apoptosis. J Clin Invest 97 (1996) 2391-2398
84. DeBiasi R.L., Edelstein C.L., Sherry B., and Tyler K.L. Calpain inhibition protects against virus-induced apoptotic myocardial injury. J Virol 75 (2001) 351-361
85. Scarabelli T.M., Pasini E., Stephanou A., et al. Urocortin promotes hemodynamic and bioenergetic recovery and improves cell survival in the isolated rat heart exposed to ischemia/reperfusion. J Am Coll Cardiol 40 (2002) 155-161
86. Inagaki K., Chen L., Ikeno F., et al. Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo. Circulation 108 (2003) 2304-2307
87. Granville D.J., Tashakkor B., Takeuchi C., et al. Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors. Proc Natl Acad Sci U S A 101 (2004) 1321-1326
88. Scarabelli T.M., Stephanou A., Pasini E., et al. Minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to smac/DIABLO, and reduces the mitochondrial leakage of cytochrome C and smac/DIABLO. J Am Coll Cardiol 43 (2004) 865-874
89. Guglin M.E., and Koul D. Cardiovascular effects of erythropoietin: anemia and beyond. Cardiol Rev 14 (2006) 200-204
90. Alam J.J. Apoptosis: target for novel drugs. Trends Biotechnol 21 (2003) 479-483
91. Haunstetter A., and Izumo S. Toward antiapoptosis as a new treatment modality. Circ Res 86 (2000) 371-376
92. Felzen B., Shilkrut M., Less H., et al. Fas (CD95/Apo-1)-mediated damage to ventricular myocytes induced by cytotoxic T lymphocytes from perforin-deficient mice: a major role for inositol 1,4,5-trisphosphate. Circ Res 82 (1998) 438-450
93. Lapointe N., Tsoporis J.N., Parker T.G., et al. Comparative effects of a vasopeptidase inhibitor vs. an angiotensin converting enzyme inhibitor on cardiomyocyte apoptosis in rats with heart failure. Mol Cell Biochem 254 (2003) 235-245
94. Spallarossa P., Garibaldi S., Altieri P., et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 37 (2004) 837-846
95. Ahmet I., Lakatta E.G., and Talan M.I. Pharmacological stimulation of beta2-adrenergic receptors (beta2AR) enhances therapeutic effectiveness of beta1AR blockade in rodent dilated ischemic cardiomyopathy. Heart Fail Rev 10 (2005) 289-296
96. Tousoulis D., Antoniades C., Vassiliadou C., et al. Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur J Heart Fail 7 (2005) 1126-1132
97. Wake R., Kim-Mitsuyama S., Izumi Y., et al. Beneficial effect of candesartan on rat diastolic heart failure. J Pharmacol Sci 98 (2005) 372-379
98. Soga M., Kamal F.A., Watanabe K., et al. Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats. Int J Cardiol 110 (2006) 378-385
99. Wang R., Miura T., Harada N., et al. Pleiotropic effects of the beta-adrenoceptor blocker carvedilol on calcium regulation during oxidative stress-induced apoptosis in cardiomyocytes. J Pharmacol Exp Ther 318 (2006) 45-52
100. Tea B.S., Dam T.V., Moreau P., Hamet P., and deBlois D. Apoptosis during regression of cardiac hypertrophy in spontaneously hypertensive rats. Temporal regulation and spatial heterogeneity. Hypertension 34 (1999) 229-235
101. Groholm T., Finckenberg P., Palojoki E., et al. Cardioprotective effects of vasopeptidase inhibition vs. angiotensin type 1-receptor blockade in spontaneously hypertensive rats on a high salt diet. Hypertens Res 27 (2004) 609-618
102. Calvillo L., Latini R., Kajstura J., et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A 100 (2003) 4802-4806
103. Moon C., Krawczyk M., Ahn D., et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci U S A 100 (2003) 11612-11617
104. Lipsic E., Schoemaker R.G., van der Meer P., Voors A.A., van Veldhuisen D.J., and van Gilst W.H. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 48 (2006) 2161-2167
105. Mitsuma W., Ito M., Kodama M., et al. Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis. Biochem Biophys Res Commun 344 (2006) 987-994
106. Lopez-Sendon J., Swedberg K., McMurray J., et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 25 (2004) 1454-1470
107. Tuch B.E. Stem cells-a clinical update. Aust Fam Physician 35 (2006) 719-721
108. Bittira B., Shum-Tim D., Al-Khaldi A., and Chiu R.C. Mobilization and homing of bone marrow stromal cells in myocardial infarction. Eur J Cardiothorac Surg 24 (2003) 393-398
109. Askari A.T., Unzek S., Popovic Z.B., et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 362 (2003) 697-703
110. Ceradini D.J., Kulkarni A.R., Callaghan M.J., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10 (2004) 858-864
111. Ma J., Ge J., Zhang S., et al. Time course of myocardial stromal cell-derived factor 1 expression and beneficial effects of intravenously administered bone marrow stem cells in rats with experimental myocardial infarction. Basic Res Cardiol 100 (2005) 217-223
112. Caplan A.I. Mesenchymal stem cells. J Orthop Res 9 (1991) 641-650
113. Makino S., Fukuda K., Miyoshi S., et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 103 (1999) 697-705
114. Hakuno D., Fukuda K., Makino S., et al. Bone marrow-derived regenerated cardiomyocytes (CMG Cells) express functional adrenergic and muscarinic receptors. Circulation 105 (2002) 380-386
115. Toma C., Pittenger M.F., Cahill K.S., Byrne B.J., and Kessler P.D. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105 (2002) 93-98
116. Rangappa S., Fen C., Lee E.H., Bongso A., and Sim E.K. Transformation of adult mesenchymal stem cells isolated from the fatty tissue into cardiomyocytes. Ann Thorac Surg 75 (2003) 775-779
117. Tomita Y, Makino S, Hakuno D, et al. Application of mesenchymal stem cell-derived cardiomyocytes as bio-pacemakers: current status and problems to be solved. Med Biol Eng Comput in press, doi:10.1007/s11517-007-0163-4.
118. Mouquet F., Pfister O., Jain M., et al. Restoration of cardiac progenitor cells after myocardial infarction by self-proliferation and selective homing of bone marrow-derived stem cells. Circ Res 97 (2005) 1090-1092
119. Wagers A.J., Sherwood R.I., Christensen J.L., and Weissman I.L. Little evidence for developmental plasticity of adult hematopoietic stem cells. Science 297 (2002) 2256-2259
120. Murry C.E., Soonpaa M.H., Reinecke H., et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 428 (2004) 664-668
121. Beltrami A.P., Barlucchi L., Torella D., et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114 (2003) 763-776
122. Oh H., Bradfute S.B., Gallardo T.D., et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci U S A 100 (2003) 12313-12318
123. Martin C.M., Meeson A.P., Robertson S.M., et al. Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart. Dev Biol 265 (2004) 262-275
124. Messina E., De Angelis L., Frati G., et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res 95 (2004) 911-921
125. Laugwitz K.L., Moretti A., Lam J., et al. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature 433 (2005) 647-653
126. Pfister O., Mouquet F., Jain M., et al. CD31- but Not CD31+ cardiac side population cells exhibit functional cardiomyogenic differentiation. Circ Res 97 (2005) 52-61
127. Moretti A., Caron L., Nakano A., et al. Multipotent embryonic isl1+ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. Cell 127 (2006) 1151-1165
128. Bishopric N.H. Evolution of the heart from bacteria to man. Ann N Y Acad Sci 1047 (2005) 13-29
129. Golan-Mashiach M., Dazard J.E., Gerecht-Nir S., et al. Design principle of gene expression used by human stem cells: implication for pluripotency. FASEB J 19 (2005) 147-149
130. Ramos C.A., Bowman T.A., Boles N.C., et al. Evidence for diversity in transcriptional profiles of single hematopoietic stem cells. PLoS Genet 2 (2006) e159
131. Amado L.C., Saliaris A.P., Schuleri K.H., et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A 102 (2005) 11474-11479
132. Nagaya N., Kangawa K., Itoh T., et al. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation 112 (2005) 1128-1135
133. Boodhwani M., Sodha N.R., and Sellke F.W. Biologically based myocardial regeneration: is there a role for the surgeon?. Curr Opin Cardiol 21 (2006) 589-594
134. Boyle A.J., Schulman S.P., Hare J.M., and Oettgen P. Is stem cell therapy ready for patients? Stem cell therapy for cardiac repair. Ready for the next step. Circulation 114 (2006) 339-352
135. Oettgen P., Boyle A.J., Schulman S.P., and Hare J.M. Cardiac stem cell therapy. Need for optimization of efficacy and safety monitoring. Circulation 114 (2006) 353-358
136. Qian H., Yang Y., Huang J., Dou K., and Yang G. Cellular cardiomyoplasty by catheter-based infusion of stem cells in clinical settings. Transpl Immunol 16 (2006) 135-147
137. van Laake L.W., Hassink R., Doevendans P.A., and Mummery C. Heart repair and stem cells. J Physiol 577 (2006) 467-478
138. Westfall M.V., Pasyk K.A., Yule D.I., Samuelson L.C., and Metzger J.M. Ultrastructure and cell-cell coupling of cardiac myocytes differentiating in embryonic stem cell cultures. Cell Motil Cytoskeleton 36 (1997) 43-54
139. Kehat I., Kenyagin-Karsenti D., Snir M., et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest 108 (2001) 407-414
140. Klug M.G., Soonpaa M.H., Koh G.Y., and Field L.J. Genetically selected cardiomyocytes from differentiating embronic stem cells form stable intracardiac grafts. J Clin Invest 98 (1996) 216-224
141. Min J.Y., Yang Y., Converso K.L., et al. Transplantation of embryonic stem cells improves cardiac function in postinfarcted rats. J Appl Physiol 92 (2002) 288-296
142. Min J.Y., Yang Y., Sullivan M.F., et al. Long-term improvement of cardiac function in rats after infarction by transplantation of embryonic stem cells. J Thorac Cardiovasc Surg 125 (2003) 361-369
143. Hodgson D.M., Behfar A., Zingman L.V., et al. Stable benefit of embryonic stem cell therapy in myocardial infarction. Am J Physiol Heart Circ Physiol 287 (2004) H471-H479
144. Laflamme M.A., Gold J., Xu C., et al. Formation of human myocardium in the rat heart from human embryonic stem cells. Am J Pathol 167 (2005) 663-671
145. Kolossov E., Bostani T., Roell W., et al. Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium. J Exp Med 203 (2006) 2315-2327
146. Ilgren E.B. Cardiomyogenic differentiation and teratocarcinoma formation in EC-derived chimaeric placentae. Placenta 4 (1983) 415-421
147. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., et al. Embryonic stem cell lines derived from human blastocysts. Science 282 (1998) 1145-1147
148. Menasche P., Hagege A.A., Scorsin M., et al. Myoblast transplantation for heart failure. Lancet 357 (2001) 279-280
149. Assmus B., Schachinger V., Teupe C., et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 106 (2002) 3009-3017
150. Strauer B.E., Brehm M., Zeus T., et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 106 (2002) 1913-1918
151. Perin E.C., Dohmann H.F., Borojevic R., et al. Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation 110 (2004) II213-II218
152. Wollert K.C., Meyer G.P., Lotz J., et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 364 (2004) 141-148
153. Strauer B.E., Brehm M., Zeus T., et al. Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: the IACT Study. J Am Coll Cardiol 46 (2005) 1651-1658
154. Assmus B., Honold J., Schachinger V., et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 355 (2006) 1222-1232
155. Janssens S., Dubois C., Bogaert J., et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 367 (2006) 113-121
156. Meyer G.P., Wollert K.C., Lotz J., et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 113 (2006) 1287-1294
157. Schachinger V., Erbs S., Elsasser A., et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 355 (2006) 1210-1221
158. Chen S.L., Fang W.W., Ye F., et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 94 (2004) 92-95
159. Erbs S., Linke A., Adams V., et al. Transplantation of blood-derived progenitor cells after recanalization of chronic coronary artery occlusion: first randomized and placebo-controlled study. Circ Res 97 (2005) 756-772
160. Menasche P., Hagege A.A., Vilquin J.T., et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol 41 (2003) 1078-1083
161. Siminiak T., Kalawski R., Fiszer D., et al. Autologous skeletal myoblast transplantation for the treatment of postinfarction myocardial injury: phase I clinical study with 12 months of follow-up. Am Heart J 148 (2004) 531-537
162. Leobon B., Garcin I., Menasche P., Vilquin J.T., Audinat E., and Charpak S. Myoblasts transplanted into rat infarcted myocardium are functionally isolated from their host. Proc Natl Acad Sci U S A 100 (2003) 7808-7811
163. Orlic D., Kajstura J., Chimenti S., et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A 98 (2001) 10344-10349
164. Balsam L.B., Wagers A.J., Christensen J.L., Kofidis T., Weissman I.L., and Robbins R.C. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 428 (2004) 668-673
165. Nygren J.M., Jovinge S., Breitbach M., et al. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med 10 (2004) 494-501
166. Wu K.H., Liu Y.L., Zhou B., and Han Z.C. Cellular therapy and myocardial tissue engineering: the role of adult stem and progenitor cells. Eur J Cardiothorac Surg 30 (2006) 770-781
167. Kamihata H., Matsubara H., Nishiue T., et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 104 (2001) 1046-1052
168. Gnecchi M., He H., Liang O.D., et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 11 (2005) 367-368
169. Caplan A.I., and Dennis J.E. Mesenchymal stem cells as trophic mediators. J Cell Biochem 98 (2006) 1076-1084
170. Kocher A.A., Schuster M.D., Szabolcs M.J., et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 7 (2001) 430-436
171. Guarita-Souza L.C., Carvalho K.A., Woitowicz V., et al. Simultaneous autologous transplantation of cocultured mesenchymal stem cells and skeletal myoblasts improves ventricular function in a murine model of Chagas disease. Circulation 114 (2006) I120-I124
172. Caplan A.I. Mesenchymal stem cells and gene therapy. Clin Orthop Relat Res (2000) S67-S70
173. Bartunek J., Croissant J.D., Wijns W., et al. Pretreatment of adult bone marrow mesenchymal stem cells with cardiomyogenic growth factors and repair of the chronically infarcted myocardium. Am J Physiol Heart Circ Physiol 292 2 (2007) H1095-H1104
174. Noiseux N., Gnecchi M., Lopez-Ilasaca M., et al. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther 14 (2006) 840-850
175. Zhang D., Zhang F., Zhang Y., et al. Combining erythropoietin infusion with intramyocardial delivery of bone marrow cells is more effective for cardiac repair. Transpl Int 20 (2007) 174-183